Argenx
ARGX
#553
Rank
A$57.26 B
Marketcap
$931.76
Share price
1.69%
Change (1 day)
52.85%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Argenx (ARGX) - Total liabilities

Total liabilities on the balance sheet as of December 2024 : A$1.10 Billion

According to Argenx 's latest financial reports the company's total liabilities are A$1.10 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Argenx - Total liabilities on balance sheet (from 2021 to 2020)

Total liabilities by year

Year Total liabilities Change
2024-12-31A$1.13 B73.36%
2023-12-31A$0.65 B38.64%
2022-12-31A$0.47 B8.06%
2021-12-31A$0.43 B-54.98%
2020-12-31A$0.96 B40.81%
2019-12-31A$0.68 B824.07%
2018-12-31A$74.42 M55.38%
2017-12-31A$47.89 M-26.39%
2016-12-31A$65.06 M356.61%
2015-12-31A$14.24 M-6.44%
2014-12-31A$15.23 M115.35%
2013-12-31A$7.07 M-11.5%
2012-12-31A$7.99 M56.07%
2011-12-31A$5.12 M92.72%
2010-12-31A$2.65 M